These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes. Shamim SA; Kumar A; Kumar R PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675 [TBL] [Abstract][Full Text] [Related]
3. PET imaging in endocrine tumours. Khan S; Lloyd C; Szyszko T; Win Z; Rubello D; Al-Nahhas A Minerva Endocrinol; 2008 Jun; 33(2):41-52. PubMed ID: 18414356 [TBL] [Abstract][Full Text] [Related]
4. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Ambrosini V; Campana D; Tomassetti P; Fanti S Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S52-60. PubMed ID: 22388622 [TBL] [Abstract][Full Text] [Related]
5. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348 [TBL] [Abstract][Full Text] [Related]
6. Preparation of ⁶⁸Ga-labelled DOTA-peptides using a manual labelling approach for small-animal PET imaging. Romero E; Martínez A; Oteo M; García A; Morcillo MA Appl Radiat Isot; 2016 Jan; 107():113-120. PubMed ID: 26492321 [TBL] [Abstract][Full Text] [Related]
7. The 'double pituitary hot spot' sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET. Law WP; Fiumara F; Fong W; Macfarlane DJ J Med Imaging Radiat Oncol; 2013 Dec; 57(6):680-3. PubMed ID: 24283556 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680 [TBL] [Abstract][Full Text] [Related]
10. Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550 [TBL] [Abstract][Full Text] [Related]
11. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. Panagiotidis E; Bomanji J PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933 [TBL] [Abstract][Full Text] [Related]
12. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience. Naswa N; Bal CS Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767 [TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807 [TBL] [Abstract][Full Text] [Related]
15. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565 [TBL] [Abstract][Full Text] [Related]
16. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627 [TBL] [Abstract][Full Text] [Related]
17. Gallium-68 PET: a new frontier in receptor cancer imaging. Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576 [TBL] [Abstract][Full Text] [Related]